genomic medicine program ronald m. przygodzki, md

49
Genomic Medicine Program Ronald M. Przygodzki, MD Associate Director, Genomic Medicine ORD March 2008

Upload: terrybear11

Post on 21-May-2015

485 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Genomic Medicine Program Ronald M. Przygodzki, MD

Genomic Medicine Program

Ronald M. Przygodzki, MDAssociate Director, Genomic Medicine

ORD

March 2008

Page 2: Genomic Medicine Program Ronald M. Przygodzki, MD

2

What is Genomic Medicine?

Genomic Medicine (personalized medicine) is healthcare tailored to an individual based on their genetic makeup (genes).

Genes are the basis for all our characteristics. There are about 25,000 genes in a human cell. In 2003, the entire human genome was

sequenced. This has resulted in an explosion in new and

advanced technologies.

Page 3: Genomic Medicine Program Ronald M. Przygodzki, MD

3

VA Genomic Medicine Program

VA launched the Genomic Medicine Program in 2006 to– Optimize medical care for veterans (for

example, avoid adverse drug reactions)– Enhance development of tests and treatments

for relevant diseases– Examine the potential of emerging genomic

technologies

Page 4: Genomic Medicine Program Ronald M. Przygodzki, MD

4

VA Genomic Medicine Program (cont’d)

VA is uniquely positioned to implement the genomics medicine program– Largest healthcare system in the US,

providing care for >5.3 million veterans– Equipped with an unrivaled electronic medical

record system– Stable and diverse patient population

Page 5: Genomic Medicine Program Ronald M. Przygodzki, MD

5

VA Genomic Medicine Program (cont’d)

Veterans may volunteer to participate– Provide blood sample for genetic analysis – Genetic information linked to their electronic

health records

Page 6: Genomic Medicine Program Ronald M. Przygodzki, MD

6

Implementation

VA Secretary established Genomic Medicine Program Advisory Committee (GMPAC)

GMPAC felt earning trust of and partnering with veterans was paramount

Recommended VA assess veterans’ knowledge, attitudes, and beliefs about genomic medicine and research participation

Page 7: Genomic Medicine Program Ronald M. Przygodzki, MD

7

Veteran Consultation Project

VA moved to assess veterans’ knowledge and attitudes in 2007.

VA established inter-agency agreement (IAA) with National Human Genome Research Institute (NHGRI) to add veteran-specific component to their ongoing project to assess public attitudes toward genomic medicine.

Page 8: Genomic Medicine Program Ronald M. Przygodzki, MD

8

Veteran Consultation Project (cont’d)

NHGRI project conducted by Genetics and Public Policy Center (GPPC) at Johns Hopkins University (PI: Kathy Hudson)

GPPC will conduct veteran focus groups and surveys over a 1-year period

Page 9: Genomic Medicine Program Ronald M. Przygodzki, MD

9

Focus Groups

Knowledge and attitudes about genomic medicine

General acceptability of proposed goals and methods of VA genomic studies

Areas of concern Methods of recruitment and consent issues Role of Veteran Service Organizations (VSOs) Expectations of potential participants with regard

to confidentiality, privacy, and security Use of research findings Return of results, ongoing communication, etc.

Page 10: Genomic Medicine Program Ronald M. Przygodzki, MD

10

Focus Groups (cont’d)

Nine focus groups were conducted (10-12 participants in each group).

Focus group guides and questions were developed in consultation with VACO.

Page 11: Genomic Medicine Program Ronald M. Przygodzki, MD

11

Focus Groups (cont’d)

Veterans were recruited from:– Local chapters of VSOs that reflect the

diversity of veterans using VA healthcare system

– VAMCs, VA Community-Based Outpatient Clinics, and VET Centers (Readjustment Counseling Centers) from various geographic regions and demographic groups

Page 12: Genomic Medicine Program Ronald M. Przygodzki, MD

12

Focus Groups (cont’d)

Pilot Southeast Northeast Midwest West

DC

Sept 19

Atlanta

Sept 26-27

Bronx

Oct 4

Denver

Oct 17-18

San Antonio

Nov 5

1. Mixed group

2. Women 5. African

American

7. Hispanic 9. Hispanic

3. Caucasian

>70

6. Caucasian

<$39K/yr

8. <30 yrs

4. African

American

10. >$55K/yr

Page 13: Genomic Medicine Program Ronald M. Przygodzki, MD

13

Initial Observations from Focus Groups

Areas of optimism include:– Altruism and a sense of community– No expectations of compensation for

participation– Community leaders to voice their

opinions/concerns– Appreciative of being consulted– Generally knowledgeable about genetics

Page 14: Genomic Medicine Program Ronald M. Przygodzki, MD

14

Initial Observations from Focus Groups (cont’d)

Areas of concern include:– Trust issues – Data privacy, security, and access– Data sharing (trusted VA and academic

researchers but not the commercial sector)– Loss of benefits

Page 15: Genomic Medicine Program Ronald M. Przygodzki, MD

15

Survey

Based on issues raised in focus groups, GPPC will develop internet-based survey

Plan to survey 850 veterans, including those receiving their healthcare through VA

Page 16: Genomic Medicine Program Ronald M. Przygodzki, MD

16

Fears about Genetic Research

Genetic information could be used against people by employers or insurers– To counteract concern, House passed the

Genetic Information Nondiscrimination Act (2007), which is expected to be passed in Senate and signed into law soon.

Page 17: Genomic Medicine Program Ronald M. Przygodzki, MD

17

Fears about Genetic Research (cont’d)

Veteran’s benefits would be affected if shown to have genetic disposition to a disease– Having dealt with genetically based diseases,

consistent position of VA that genetic disease that first appears during a period of active service constitutes a service-connected condition

– Genomic medicine program aims only to improve effectiveness of VA’s health care system

Page 18: Genomic Medicine Program Ronald M. Przygodzki, MD

18

Data and Sample Sharing Policy

Samples and data will only be available to VA researchers.

Policy may change to reflect veterans’ attitudes revealed in Veteran Consultation Project focus groups and survey.

Page 19: Genomic Medicine Program Ronald M. Przygodzki, MD

19

GMPAC Working Groups

Ethics Advisory - ethical considerations, esp. informed consent of special populations

Hereditary Non-Polyposis Colon Cancer (HNPCC) - research on routine genetic/genomic analysis for clinical management of HNPCC & sporadic colon cancer

Endocrine Tumors - research on routine genetic/genomic analysis for clinical management of tumors with known genetic abnormalities

Page 20: Genomic Medicine Program Ronald M. Przygodzki, MD

20

Infrastructure Development

DNA Bank/Biorepository (Boston VA)– About 30,000 blood samples collected as part of CSP

trials Pharmacogenomics Analysis Laboratory (Little

Rock) Educational tools—collaboration between VA

Employee Education Resource Center and National Coalition ofr Health Professionals Education in Genetics (NCHPEG)

Assessing current capabilities and activities related to genomics at VAMCs

Page 21: Genomic Medicine Program Ronald M. Przygodzki, MD

21

Ongoing Genomics/ Genetics-Related Projects

VA funds 142 investigator-initiated Merit Review projects– Cover wide spectrum of conditions prevalent

in veterans: schizophrenia, PTSD, bipolar disorder, substance abuse, Alzheimer’s, cardiovascular disease, diabetes, cancer (prostate, breast, colon, bladder, lung), stroke, chronic viral infections, autoimmune disorders, Gulf War Illness, etc.

– Genetic-association, pharmacogenomics– Candidate gene analysis, SNP analysis,

linkage studies, microarrays, si RNA, gene expression

Page 22: Genomic Medicine Program Ronald M. Przygodzki, MD

22

Studies in Planning

Serious Mental Illness Cohort Study – Concept letter approved for

planning/submitting full proposal to CSP – Goal to develop 3 longitudinal cohorts, each

consisting of 5000 veterans suffering from 1) schizophrenia or 2) bipolar disorder or a 3) control group

– Genome-wide association studies• Variants that contribute to functional disability• Responsiveness to therapy• Drug toxicity

Page 23: Genomic Medicine Program Ronald M. Przygodzki, MD

23

Studies in Planning (cont’d)

PTSD Genetics Working/Planning Group– Goal to explore/ define basis to conduct

research on PTSD through development of new/ expansion of current cohorts (e.g., ongoing CSP clinical trials).

– Via careful clinical characterization and genetic analyses, cohort should be longitudinally available.

– Use cohort to determine genetic variants contributing to PTSD risk, as well as treatment response and outcomes.

Page 24: Genomic Medicine Program Ronald M. Przygodzki, MD

24

Interactions With Other Organizations

VA involved in ongoing discussions and in working groups with: – Pharmacogenetic Research Network, supported by

several NIH Institutes– National Human Genome Research Institute

(NHGRI)– Institute of Medicine Roundtable on Translating

Genomic-Based Research for Health– American Health Information Community (AHIC)

Page 25: Genomic Medicine Program Ronald M. Przygodzki, MD

Tissue Banking Policies

January 2008

Page 26: Genomic Medicine Program Ronald M. Przygodzki, MD

26

Topics Covered

Definitions of human biological specimens, banked specimens, and de-identified

On-site tissue banks Off-site tissue banks Specimens stored at non-academic, for-

profit institutions Applying for an off-site waiver Elements required in an informed consent

Page 27: Genomic Medicine Program Ronald M. Przygodzki, MD

27

Human Biological Specimens

Any material derived from a human subject—such as blood, urine, tissues, organs, hair, nail clippings, or any other cells or fluids

Whether collected for research purposes or as residual specimens from diagnostic, therapeutic, or surgical procedures

Page 28: Genomic Medicine Program Ronald M. Przygodzki, MD

28

Banked Specimens

Biological specimens collected and stored for future research purposes that are beyond the scope of work described in the original protocol and informed consent

OR Biological specimens collected under a

protocol designed for banking of specimens

Page 29: Genomic Medicine Program Ronald M. Przygodzki, MD

29

Non-Banked Human Biological Specimens

Human biological specimens collected under a VA-approved protocol that are used for only the specific purposes defined in the protocol and are destroyed when the specific testing/use is completed or at the end of the protocol

Important Notes:– If specimens are stored off-site at a non-profit

institution 5 years, then the investigator must obtain a waiver from ORD.

– If specimens are stored off-site at a non-academic, for-profit institution for >3 months, a waiver must be obtained from ORD.

Page 30: Genomic Medicine Program Ronald M. Przygodzki, MD

30

Non-Banked Specimens

If the specimens are sent to a non-VA institution for testing as defined in the protocol, once the specific analyses are performed, the remainder of the specimens must be destroyed or returned to the VA for destruction.

If the specimens are destroyed at another institution, that institution must certify the destruction of the specimens in writing.

Page 31: Genomic Medicine Program Ronald M. Przygodzki, MD

31

De-identified De-identified data is health or other information

about an individual that:

Does not contain any of the 18 HIPAA identifiersAND

Is de-identified according to the Common Rule

Coded information is not considered de-identified if the tissue bank or data coordinating center has access to the codes.

Page 32: Genomic Medicine Program Ronald M. Przygodzki, MD

32

HIPAA Identifiers

1. Names or initials

2. All geographic subdivisions smaller than a state

3. All elements of dates except the year and all ages over 89

4. Telephone numbers

5. Fax numbers

6. E-mail addresses

7. Social Security numbers (or scrambled SSNs)

8. Medical record numbers

9. Health plan beneficiary numbers

Page 33: Genomic Medicine Program Ronald M. Przygodzki, MD

33

HIPAA Identifiers (cont’d)

10. Account numbers

11. Certificate or license numbers

12. Vehicle identifiers

13. Device identifiers and serial numbers

14. URLs

15. IP addresses

16. Biometric identifiers, including finger and voice prints

17. Full-face photographs and any comparable images

18. Any other unique identifying number, characteristic, or code

Page 34: Genomic Medicine Program Ronald M. Przygodzki, MD

34

On-Site Tissue Banks

A tissue bank established at a VA site by a VA-paid investigator does not require ORD approval.

The ACOS/R or research office should maintain records of all tissue banks within the facility.

Page 35: Genomic Medicine Program Ronald M. Przygodzki, MD

35

On-Site Tissue Banks (cont’d)

If a VA site does not have the resources to bank specimens, then they may be banked at any VA site that has an established tissue bank.

Alternatively, specimens may be banked at the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) core laboratory at the Boston VA. It serves as the Cooperative Studies Program (CSP) Genetic Tissue Core Laboratory.

Either option is considered on-site banking.

Page 36: Genomic Medicine Program Ronald M. Przygodzki, MD

36

Off-Site Tissue Banks

The researcher must obtain a waiver from ORD before banking human biological specimens at an off-site location.

Off-site tissue banks are approved on a per protocol basis.

Exception: National Cancer Institute (NCI)-sponsored cooperative tissue banks listed on the next slide. As a result of a letter of understanding with the NCI, these banks are designated as VA-approved if they are used for one of their protocols (for example, the SWOG-supported tissue bank can be used for SWOG protocols without ORD approval).

Page 37: Genomic Medicine Program Ronald M. Przygodzki, MD

37

VA-Approved NCI Tissue Banks

Clinical Trials Cooperative Groups Tissue Resources – American College of Surgeons Oncology Group (ACOSOG) – Cancer and Leukemia Group B (CALGB) – Eastern Cooperative Oncology Group (ECOG) – Gynecologic Oncology Group (GOG) – North Central Cancer Treatment Group (NCCTG) – National Surgical Adjuvant Breast and Bowel Project (NSABP) – Radiation Therapy Oncology Group (RTOG) – Southwest Oncology Group (SWOG)– National Cancer Institute of Canada Clinical Trials Group (NCIC

CTG) Cooperative Breast Cancer Tissue Resource Cooperative Human Tissue Network Gynecologic Oncology Group Tissue Network Cancer Prevention Network

Page 38: Genomic Medicine Program Ronald M. Przygodzki, MD

38

Banked Specimens

Specimens may not be banked at a non-academic, for-profit institution

Specimens must be labeled with a code that does not contain any of the 18 HIPAA identifiers.

The key to the code must be maintained at the VA unless there is a compelling reason otherwise.

Page 39: Genomic Medicine Program Ronald M. Przygodzki, MD

39

Data Related to Banked Specimens

If data linked to the sample leaves the VA, then it must be de-identified or stored in a database that is encrypted according to FIPS 140-2 standards.

See VA Handbook 6500 “Information Security.”

Page 40: Genomic Medicine Program Ronald M. Przygodzki, MD

40

Non-Banked Specimens Stored at Non-Academic

For-Profit Sites If the specimens are held for >3 months, then a

waiver must be obtained from ORD. Only analyses/tests listed in the protocol and

informed consent may be performed. The code must be maintained at the VAMC. All specimens and associated data must be de-

identified. DNA and RNA may not be analyzed. The company must inform the PI in writing when

samples are destroyed.

Page 41: Genomic Medicine Program Ronald M. Przygodzki, MD

41

Non-Banked Specimens Stored at Non-Academic For-Profit Sites (cont’d)

HIPAA authorization must expire. Case reports may not contain initials if they

leave VA. Specimens must be destroyed upon request of

the subject. Before company personnel may view files at the

VA, they must complete VA security and privacy training.

Specimens must be destroyed within 1 year of the study completion date.

Page 42: Genomic Medicine Program Ronald M. Przygodzki, MD

42

Application Process

The investigator must complete VA form 10-0436. This is a pdf form that can be filled in and saved using Acrobat Reader version 7 or higher (http://www.va.gov/vaforms/medical/pdf/vha-10-0436-fill.pdf).

The information requested on page 5 of the application can be scanned and attached to the pdf or to the e-mail. – Biographical sketch of the PI– Research protocol– Tissue bank manual or SOPs– VA consent form

Page 43: Genomic Medicine Program Ronald M. Przygodzki, MD

43

Application Process (cont’d)

The application should be e-mailed to Marilyn Mason ([email protected]). The ACOS/R must be carbon copied.

Alternatively, the form and requested information can be mailed to the address given on the form.

Page 44: Genomic Medicine Program Ronald M. Przygodzki, MD

44

Application Process (cont’d)

After the application is reviewed, the PI and ACOS/R will receive a memo listing any issues found with the application. Frequently, the informed consent needs to be modified.

Page 45: Genomic Medicine Program Ronald M. Przygodzki, MD

45

Multi-Site Trials

If several VAMCs are planning to participate in the same clinical trial, then only one of the VA sites needs to apply for a waiver.

A list of multi-site clinical trials in which more than one VAMC is participating is posted on the VA R&D web site. (http://www.research.va.gov/programs/tissue_banking)

Page 46: Genomic Medicine Program Ronald M. Przygodzki, MD

46

Informed Consent

Several elements must be included in an informed consent when the protocol involves banking–either on-site or off-site– of human biological specimens.

The elements are important for transparency to the subject.

The list of elements is posted on the VA R&D web site, and some are given on the next slide.

Page 47: Genomic Medicine Program Ronald M. Przygodzki, MD

47

Informed Consent (cont’d)

Some informed consent elements– Types of samples stored and length of time to

be stored– Name and location of tissue bank– Types of future studies– Subject may withdraw from the study and

request that his/her samples be destroyed– If the specimen will be shared with other

researchers for approved research protocols

Page 48: Genomic Medicine Program Ronald M. Przygodzki, MD

48

Informed Consent (cont’d)

The informed consent does not need to narrowly specify the future uses of the banked specimens.

But if it is not specific, in the consent form or during the consent process, the PI should explain what such phrases as “related diseases” or “unspecified research” means for the use of the sample and the impact on the subject.

Page 49: Genomic Medicine Program Ronald M. Przygodzki, MD

49

Contact Information

For additional information and questions, contact Marilyn Mason– E-mail: [email protected]– Phone: 202-254-0496– Fax: 202-254-0521